ArticleScientific reports2025
The TRPV4-YAP axis mediates cytoskeletal and extracellular matrix remodeling in trabecular meshwork cells as a novel glaucoma mechanism.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TRPV4 regulates intraocular pressure through trabecular meshwork contractility and fibrosis.Channels (Austin, Tex.) · 2026Review
- Transformative biomechanics and mechanobiology breakthroughs shaping the future of health and medicine.Innovation (Cambridge (Mass.)) · 2026Review
- Bioelectric fields drive pulmonary epithelial proliferation through PI3K/AKT/GSK3β signaling.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Transient Receptor Potential Vanilloid 4 (TRPV4), a non-selective cation channel in trabecular meshwork (TM) tissue, is activated by forces like deformation and shear stress, playing a critical role in intraocular pressure (IOP) regulation. However, the mechanisms by which TRPV4 mediates TM cells responses to elevated intraocular pressure (IOP), along with the resulting regulatory outcomes, remain incompletely understood. In vitro, TM cells were mechanically stretched, and the effects on TRPV4 activation and calcium influx were evaluated via confocal microscopy, Western blotting, and immunofluorescence. Pharmacological agonists and inhibitors were used to investigate signaling mechanisms. In vivo, ocular hypertension (OHT) was induced in mice, and IOP was measured following drug treatments. Subsequently, IOP was measured after drug administration. Transcriptome sequencing was performed to detect TRPV4 activation-induced alterations in RNA expression and to explore associated regulatory pathways. Mechanical stretch significantly reduced YAP1 mRNA expression in TM cells. TRPV4 activation induced YAP nuclear translocation, which was inhibited by HC067047, confirming TRPV4-YAP signaling. Transcriptome sequencing confirmed that the PI3K/AKT signaling pathway is crucial in mediating YAP activation. In vivo, HC067047 and VP treatment significantly lowered IOP and reduced the accumulation of ECM proteins in TM tissues. Our study demonstrates the critical role of TRPV4-YAP signaling in TM cell function and IOP regulation. These findings indicate that targeting the TRPV4-PI3K/AKT-YAP axis may offer novel therapeutic strategies for glaucoma..
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.